ALK and non-small cell lung carcinoma: SNS indication #2: Lorlatinib monotherapy is indicated for adult patients with ALK-positive advanced NSCLC not previously treated with an ALK TKI [28].Clinical evidence approval SNS indication #2: Phase III B7461006 CROWN study, a multicenter, randomized (1:1), open-label, controlled trial with active treatment (crizotinib), evaluating efficacy of lorlatinib in patients who had not received prior treatment.